Bharat Biotech

Bharat Biotech, Alopexx partner to develop new broad-spectrum vaccine

Bharat Biotech, based in Genome Valley, Hyderabad, has a portfolio of vaccines and bio-therapeutics, including COVID-19 vaccines and novel vaccines for various infectious diseases

Bharat Biotech partners with Alopexx to develop anti-microbial vaccine

Bharat Biotech on Wednesday announced a collaboration with Alopexx Inc for development and commercialisation of the latter's broad-spectrum anti-microbial vaccine in India and other low income countries. As part of the collaboration, the companies will co-develop and commercialise the vaccine -- AV0328, in India and other licensed territories, Bharat Biotech said in a statement. Alopexx would be entitled to a one-time upfront payment and milestone payments, as well as royalties on future sales of AV0328 in the licensed territories, it added. "Our goal is to develop solutions to reduce anti-microbial resistance through vaccination. This collaboration aligns with our mission to provide safe, affordable, and high-quality vaccines to combat infectious diseases globally," Bharat Biotech Executive Chairman Krishna Ella said. Alopexx CEO Daniel Vlock said, this collaboration brings the company one step closer to addressing the critical need for affordable, broad-spectrum antimicrobial ..

Bharat Biotech launches oral cholera vaccine amid global shortage

With only one manufacturer currently supplying OCVs worldwide, there has been a deficit of approximately 40 million doses annually

Bharat Biotech launches oral cholera vaccine after positive phase 3 trial

Bharat Biotech in a release said it plans to bridge a worldwide deficit of 40 million doses per year through Hillchol

Bharat Bio moves to include ICMR as co-owner in patent filings for Covaxin

As firm corrects 'inadvertent' mistake, experts feel it's not uncommon to add new parties to patent filings

Bharat Biotech moves to adds ICMR as co-owner of Covid-19 vaccine patent

Bharat Biotech was working on developing the Covid-19 vaccine as a top priority to ensure product availability at the earliest

ICMR distances itself from BHU study on Covaxin, calls it 'poorly designed'

Bharat Biotech had then rebuked the BHU study, saying that its indigenously developed Covid vaccine Covaxin has shown an 'excellent safety track record' in various studies

Covaxin has 'excellent record', says Bharat Biotech after study cites risks

The research conducted by BHU indicated that Covaxin increased the rare risk of stroke and Guillain-Barre syndrome, among other issues

After Covishield, new study 'finds' side effects in Covaxin recipients

In observational study on Bharat Biotech's Covaxin recipients, about one-third of participants reported adverse events

Covaxin developed with focus on safety first, says Bharat Biotech

Bharat Biotech on Thursday asserted that its Covid-19 vaccine Covaxin is safe and devoid of any side-effects amid AstraZeneca's admission that Covishield could cause complications in rare cases. In a statement, the company stated that Covaxin was developed with a single-minded focus on safety first, followed by efficacy. The vaccine was evaluated in more than 27,000 subjects as part of its licensure process, Bharat Biotech stated. It was licensed under restricted use in clinical trial mode, where detailed safety reporting was carried out for several hundred thousand subjects, it noted. The vaccine was also evaluated by the Union Ministry of Health, it said. Besides, safety monitoring (pharmacovigilance) was continued throughout the product life cycle of Covaxin, it stated. All the above studies and safety follow-up activities have demonstrated an excellent safety record for Covaxin without any vaccine-associated incidents of blood clots, thrombocytopenia, TTS, VITT, pericarditis,

Bharat Biotech co-founder Krishna Ella takes helm as President of IVMA

Ella takes over the presidency from Adar C Poonawalla, who held the post from 2019 to March 2024

Bharat Biotech, Bilthoven Biologicals collaborate for oral polio vaccines

Bilthoven Biologicals will produce the vaccines for distribution in India and worldwide

Bharat Biotech, Bilthoven Biologicals collaborate for oral polio vaccines

Bharat Biotech on Tuesday said it has collaborated with the Netherlands-based Bilthoven Biologicals B.V, a wholly-owned arm of Serum Institute of India, to strengthen production and supply security of oral polio vaccines. An agreement has been signed between the two partners under which Bharat Biotech will procure drug substances for the production of oral polio vaccines (OPVs) to be supplied within India and globally, the company said in a statement. Through this collaboration, Bharat Biotech and Bilthoven Biologicals (BBio) will jointly obtain regulatory approvals and licences required to commercially manufacture OPVs in India for global supplies from drug substances manufactured in the Netherlands at BBio, it added. "This collaboration...exemplifies cooperation between vaccine companies, ensuring a secure supply of oral polio vaccines and fortifies the nation's mission to eradicate polio," Bharat Biotech Executive Chairman Krishna Ella said. Serum Institute of India CEO Adar ...

Bharat Biotech's TB vaccine MTBVAC begins clinical trials in India

The trials will assess the vaccine's safety, immune response, and efficacy in preventing TB in adults and adolescents. MTBVAC has been developed after research spanning over three decades

Shot stories: Meet Bharat Biotech's Krishna Ella, the man behind Covaxin

As the pandemic raged, India developed its own vaccine. Those weren't easy days, Ella, the man behind Covaxin, tells Sohini Das

Bharat Biotech, University of Sydney ink MoU for vaccine research

The international agreement aims to foster strong collaborations between sectors and organisations to develop innovative methods for tackling future epidemics and infectious diseases

TMS Ep529: Acquisition appetite, Krishna Ella, markets, sports associations

Why are business families in acquisition mode? How does Krishna Ella view Bharat Biotech's future? Is it time to bottom-fish in stock market? What happens when sports associations are suspended?

Bharat Biotech plans to invest Rs 3,000-4,000 crore in post-Covid shift

Not thinking about an IPO as of now, says chairman

We have one of the best TB vaccines in the world: Bharat Bio's Krishna Ella

'We are working on the TB vaccine as the Prime Minister's view is also to eradicate TB from the country'

Bharat Biotech picks up 20% stake in Eastman Exports Global Clothing

The Bharat Biotech Group has picked up 20 per cent in Tamil Nadu-based knitwear firm Eastman Exports Global Clothing Private Ltd, for an undisclosed amount. A press release from Eastman Exports said it will use the new investment for capital expenditure, strengthening backward integration and customer acquisition among others. The funds will also help the company expand its presence in the global apparel industry, especially at a time when other countries are facing a slowdown and to capture the overall China Plus One Strategy of divesting manufacturing away from a single country. Managing Director of Bharat Biotech, Suchitra Ella said, We are fully committed to the Make in India strategy across industries. India is one of the few vertically integrated countries in cotton-based apparels, our vision is to grow this industry and support manufacturing from India to the world. Our vision of supporting rural and semi-urban communities, especially women is addressed through this ...